US FDA Approves Dupilumab To Treat Atopic Dermatitis In Pediatric Patients
The Food and Drug Administration (FDA) of the United States has approved Dupilumab (Dupixent) for the children aged between 6 months to 5 years suffering with moderate tp serious atopic dermatitis whose disease has not been adequately controlled with the topical prescription therapies. The regulatory filings for this particular age group have been underway by […]
Continue Reading